RESEARCH & LABORATORY USE ONLY

UK-BASED SUPPLIER · ESTABLISHED 2023

Research-grade peptides, verified by third-party analysis.

Supplied to independent researchers, academic laboratories, and accredited institutions. Purity verified by HPLC and mass spectrometry on every batch.

≥98%

HPLC PURITY

3pm

DISPATCH CUT-OFF

-20°C

COLD CHAIN

COA

PER BATCH

CATALOGUE

Most studied compounds

View all 18 →
BSR INTELLIGENCE

Latest from the peptide industry

All briefings →

Industry & Community

Peptide CDMO Consolidation Accelerates: Samsung Biologics Launches Formal Tender for PolyPeptide as CordenPharma Closes AmbioPharm Deal

Samsung Biologics published its formal tender offer prospectus for Swiss peptide CDMO PolyPeptide Group on 31 August 2026, opening a ten-day cooling-off period ahead of the main acceptance window. The CHF 1.46 billion all-cash bid — carrying a 40 per cent premium to the pre-speculation share price — arrives weeks after CordenPharma completed its acquisition of AmbioPharm, signalling a sharp acceleration in consolidation among specialist peptide contract manufacturers.

02 Sep 2026

Pharma & GLP-1

CagriSema: The Amylin–GLP-1 Combination With an FDA Decision Due in Q4 2026, a Mixed Trial Record, and No MHRA Pathway Announced

Novo Nordisk's CagriSema — a fixed-dose weekly injection combining semaglutide and the long-acting amylin analogue cagrilintide — is awaiting an FDA decision in the fourth quarter of 2026. The compound produced up to 22.7% weight loss in pivotal trials but failed to demonstrate non-inferiority against tirzepatide in a head-to-head study. No MHRA or EMA regulatory pathway has been announced for the UK or EU.

01 Sep 2026

Reputational Risks

Paradigm Peptides Owner Sentenced to 70 Months: What the First Major Criminal Conviction in the Research-Use-Only Market Means for Research Procurement

A US federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison on 30 July 2026, after he admitted importing unapproved drugs from China and India and misrepresenting them as domestically manufactured, FDA-registered products. The case is widely regarded as the first significant criminal prosecution in the largely unregulated "research-use only" peptide marketplace, and it carries direct implications for research procurement officers assessing supplier risk.

31 Aug 2026

HPLC analysis instrument
01 · DOCUMENTATION

Every batch, documented.

HPLC purity analysis, mass spectrometry confirmation, and batch traceability — downloadable per product, matched to the batch code on your vial.

View our methodology →
Research vials in storage rack
02 · STORAGE

Cold chain maintained.

Lyophilised product held at -20°C in temperature-controlled storage from receipt to dispatch. Stability guaranteed under documented conditions.

Storage protocols →
Research compound vials ready for dispatch
03 · DISPATCH

Same-day, plain packaging.

Orders placed before 3pm, Monday to Friday, dispatched the same working day. Tracked UK delivery, discreet unbranded packaging as standard.

Shipping & returns →